Permanente Medicine
Home | Contact

MTM2017

Monica Ter-Minassian, ScD

Research Scientist

Monica.Ter-Minassian@kp.org

Education:

ScD in Environmental and Occupational Epidemiology, Harvard School of Public Health, 2009
MS in Epidemiology, Harvard School of Public Health, 2006
MS in Cell and Molecular Biology, Genetic Counseling Program, Brandeis University, 1999

Professional Affiliations:

American Society of Hematology
American Society of Clinical Oncology
North American Neuroendocrine Tumor Society

 

Monica Ter-Minassian ScD, is a research scientist at the Mid-Atlantic Permanente Research Institute (MAPRI). Her expertise is cancer epidemiology and genetic and molecular epidemiology. Monica designs and conducts research focused primarily on cancer prevention and survival and on the care for patients with sickle cell disease. She has collaborated with Johns Hopkins Medicine and MAPMG physicians on projects evaluating screening and preventative therapies for patients at higher risk for breast or ovarian cancer, and a project evaluating gastric cancer outcomes for patients treated with neoadjuvant therapy and gastrectomy or with gastrectomy alone. Monica also works with the FDA Sentinel project on drug and vaccine safety, surveillance and data quality improvement. One project included a literature review on data capture and improvement of the race and ethnicity variables in claims and integrated healthcare systems databases. Prior to joining Kaiser Permanente, she was a joint Research Fellow at the Dana-Farber Cancer Institute and the Harvard School of Public Health where she studied factors related to neuroendocrine tumor risk and survival.

Dr. Ter-Minassian is excited to be a part of the MAPRI team and develop new research to improve surveillance and patient care for cancer, sickle cell disease and drug safety.

Research Interests:

Cancer and oncology epidemiology, genetic and molecular epidemiology, sickle-cell disease, drug safety surveillance

For a full list of publications, please see Dr. Ter-Minassian’s Curriculum Vitae.

Recent Publications

  1. Ter-Minassian M, DiNucci A, Barrie I, Schoeplein R, Chakravarty A, Hernández-Muñoz J. Improving data capture of race and ethnicity for the Food and Drug Administration Sentinel database: a narrative review. Ann Epidemiol. 2023 Oct;86:80-89.e2. doi: 10.1016/j.annepidem.2023.07.006. Epub 2023 Jul 20. PMID: 37479122.
  2. Ter-Minassian M, Basra S, Watson E, Derus A Horberg M. Mortality data comparison of data from the National Death Index and a large US integrated health care system observational cohort. BMJ Health Care Inform. 2023 Jul;30(1):e100737. doi:10.1136/bmjhci-2023-100737. PMCID: PMC10335466.
  3. Feigelson HS, Clarke CL, Van Den Eeden SK, Weinmann S, Burnett-Hartman AN, Rowell S, Scott SG, White LL, Ter-Minassian M, Honda SAA, Young DR, Kamineni A, Chinn T, Lituev A, Bauck A, McGlynn EA. The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship. BMC Cancer. 2022 Feb
    25;22(1):209. PMCID: PMC8876075.
  4. Ter-Minassian M, Schaeffer ML, Jefferson CR, Shapiro SC, Suwannarat P, Visvanathan K. Screening and Preventative Strategies for Patients at High Risk for Breast Cancer. JCO Oncol Pract. 2021 Apr;17(4):e575-e581.
  5. Burnett-Hartman AN, Udaltsova N, Kushi LH, Neslund-Dudas C, Rahm AK, Pawloski PA, Corley DA, Knerr S, Feigelson HS, Hunter JE, Tabano DC, Epstein MM, Honda SA, Ter-Minassian M, Lynch JA, Lu CY. Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clin Cancer Inform. 2019 Sep;3:1-10.
  6. Ter-Minassian M, Lanzkron S, Derus A, Brown E, Horberg MA. Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease. Journal of the National Medical Association. 2018 Jun 22 [Epub]. 2019 Feb;111(1):54-61.
  7. Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, Lin X, Gabriel S, Dinet J, Kulke MH. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist. 2017 Feb;22(2):165-172. PMC5330705.
  8. Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016 Nov;45(10):1386-1393. PMCID: PMC5067972.
  9. Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P,Christiani DC, Kulke MH. Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr Relat Cancer. 2016 Aug;23(8):587-94.
  10. Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T, Brais LK, Daskalova A, Heafield R, Lin X, Christiani DC, Fuchs CS, Ogino S, Kulke MH. Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol. 2013 Sep 20;31(27):3418-25.
  11. Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Liu G, Christiani DC, Kulke MH. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocrine Related Cancer. 2013. 22;20(2):187-96.
  12. Zhao Y, Yu H, Zhu Y, Ter-Minassian M, Peng Z, Shen H, Diao N, Chen F. Genetic association analysis using sibship data: a multilevel model approach. PLoS One. 2012;7(2):e31134.
  13. Zhai R, Zhao Y, Liu G, Ter-Minassian M, Wu IC, Wang Z, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer. 2012 Feb1;118(3):804-11.

Current Studies

  1. Gastric Cancer Surgical Outcomes
    Goal: The goal of this collaborative pilot project with Johns Hopkins University is to compare predictive comorbidity indexes for surgical outcomes of patients with gastric cancer, including overall survival and readmission rates.
    Funder: Community Benefit, Kaiser Permanente
    Role: Principal Investigator
  2. Oncology Epidemiology
    Goal: The goal of this project is to work with the KPMAS cancer registry to monitor cancer incidence, treatment and
    survival of all patients diagnosed with cancer at Kaiser Permanente Mid-Atlantic States.
    Funder: Community Benefit, Kaiser Permanente
    Role: Principal Investigator
  3. Sentinel Data Partner Infrastructure and Querying 
    Goal: Contract to provide drug safety surveillance data for the multisite Federal Drug Administration Sentinel project.
    Funder: FDA HHSF223201400030I
    Role: Principal Investigator
  4. Sickle Cell Disease Registry
    Goal:     The goal of this project is to monitor Sickle Cell Disease incidence, treatment, and vaccinations of patients
    diagnosed at Kaiser Permanente Mid-Atlantic States.
    Funder: Community Benefit, Kaiser Permanente
    Role: Principal Investigator
Back To Top